Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin.

Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, Nagy ZS, Kahan BD, Kirken RA. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15; 99(2):680-9.

View in: PubMed

subject areas

Administration, Oral
Animals
Cell Line
Cells, Cultured
Cyclosporine
DNA-Binding Proteins
Dose-Response Relationship, Drug
Drug Interactions
Drug Synergism
Enzyme Inhibitors
Graft Survival
Heart Transplantation
Humans
Immunosuppressive Agents
Interleukins
Janus Kinase 2
Janus Kinase 3
Jurkat Cells
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
MAP Kinase Signaling System
Milk Proteins
Phosphorylation
Prodigiosin
Protein Processing, Post-Translational
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Pyrroles
Rats
Rats, Inbred BUF
Rats, Inbred WF
Sirolimus
STAT5 Transcription Factor
T-Lymphocytes
Trans-Activators

authors with profiles

Robert Kirken

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support